150 related articles for article (PubMed ID: 32956004)
1. Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan.
Bun S; Yonemori K; Sunadoi H; Nishigaki R; Noguchi E; Okusaka T; Nishida T; Fujiwara Y
JCO Oncol Pract; 2021 Mar; 17(3):e416-e425. PubMed ID: 32956004
[TBL] [Abstract][Full Text] [Related]
2. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
Shimazawa R; Ikeda M
Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
[TBL] [Abstract][Full Text] [Related]
3. Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database.
Tanemura N; Asawa M; Kuroda M; Sasaki T; Iwane Y; Urushihara H
World J Pediatr; 2019 Feb; 15(1):92-99. PubMed ID: 30506238
[TBL] [Abstract][Full Text] [Related]
4. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects.
Nagai S; Ozawa K
Invest New Drugs; 2016 Dec; 34(6):777-791. PubMed ID: 27538583
[TBL] [Abstract][Full Text] [Related]
6. Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial.
Ishimaru S; Shimoi T; Sunami K; Nakajima M; Ando Y; Okita N; Nakamura K; Shibata T; Fujiwara Y; Yamamoto N
Int J Clin Oncol; 2024 Feb; 29(2):89-95. PubMed ID: 38112833
[TBL] [Abstract][Full Text] [Related]
7. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
Kocs D; Fendrick AM
Am J Manag Care; 2003 May; 9(5):393-400; quiz 401-2. PubMed ID: 12744301
[TBL] [Abstract][Full Text] [Related]
8. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.
Zarkavelis G; Amylidi AL; Verbaanderd C; Cherny NI; Metaxas Y; de Vries EGE; Zygoura P; Amaral T; Jordan K; Strijbos M; Dafni U; Latino N; Galotti M; Lordick F; Giuliani R; Pignatti F; Pentheroudakis G
ESMO Open; 2023 Feb; 8(1):100604. PubMed ID: 36870739
[TBL] [Abstract][Full Text] [Related]
9. An institutional audit of the use of novel drugs in pediatric oncology.
Lee J; Gillam L; Kouw S; McCarthy MC; Hansford JR
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1404. PubMed ID: 33939320
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.
Mullins CD; Montgomery R; Abernethy AP; Hussain A; Pearson SD; Tunis S;
J Clin Oncol; 2012 Feb; 30(6):661-6. PubMed ID: 22253467
[TBL] [Abstract][Full Text] [Related]
11. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
12. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
Salvo I; Landoni G; Mucchetti M; Cabrini L; Pani L
Paediatr Anaesth; 2014 Jun; 24(6):625-31. PubMed ID: 24796404
[TBL] [Abstract][Full Text] [Related]
13. Paving the Path for Sustainable and Responsible Off-Label Use of Pharmaceutical Products in Europe.
Díaz Hernández M; Roslin W; Mansnérus J
Eur J Health Law; 2024 Mar; 31(2):129-152. PubMed ID: 38594021
[TBL] [Abstract][Full Text] [Related]
14. [Analysis on off-label use of drugs in pediatric guidelines and consensus published by Chinese authors].
Meng M; Wang P; Lan H; Lei WJ; Shen Q; Zhou Q; Su RF; Lyu M; Yang B; Luo XF; Lei RB; Hou TC; Li Q; Chen Y
Zhonghua Er Ke Za Zhi; 2022 Mar; 60(3):215-220. PubMed ID: 35240741
[No Abstract] [Full Text] [Related]
15. Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis.
Seidenschnur KEK; Dressler C; Weller K; Nast A; Werner RN
J Dtsch Dermatol Ges; 2017 Nov; 15(11):1103-1109. PubMed ID: 29064628
[TBL] [Abstract][Full Text] [Related]
16. Experience and prospects for the use of off-label drugs in oncology.
Drogovoz SM; Starikov VI; Ivantsyk LB; Shchokina KG
Exp Oncol; 2021 Mar; 43(1):1-5. PubMed ID: 33785726
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Drugs Approved by Public Knowledge-Based Applications (Kouchi-shinsei) During the Last Two Decades in Japan.
Maeda H; Fukuda Y; Uchida M
Clin Pharmacol Ther; 2021 Oct; 110(4):1127-1135. PubMed ID: 34110632
[TBL] [Abstract][Full Text] [Related]
18. Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.
Bauters T; Heenen D; Norga K; Van Damme A; Uyttebroeck A; Laureys G
Eur J Pediatr; 2021 Sep; 180(9):3067-3071. PubMed ID: 34137919
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of off-label use of oral oncolytics at a community cancer center.
Kalis JA; Pence SJ; Mancini RS; Zuckerman DS; Ineck JR
J Oncol Pract; 2015 Mar; 11(2):e139-43. PubMed ID: 25604593
[TBL] [Abstract][Full Text] [Related]
20. [Public financing for off-label use of drugs].
Hammerman A; Lipschitz Y; Pliskin J; Greenberg D
Harefuah; 2011 Feb; 150(2):163-7, 204. PubMed ID: 22164947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
